Rimegepant Sulfate
FDA-approved product (tablet, orally disintegrating, oral), marketed as Nurtec Odt.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Migraine disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Calcitonin gene-related peptide (cgrp) antagonists
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Rimegepant Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- IloperidoneExisting use: Psychosis, Schizophrenia45.8% AI-predicted activityagainst E. coli32 registered studies
- Thiethylperazine MalateExisting use: Allergic disease45.8% AI-predicted activityagainst E. coliNo documented evidence found
- Fostamatinib DisodiumExisting use: Autoimmune thrombocytopenic purpura, Hemorrhage, Thrombocytopenia45.7% AI-predicted activityagainst E. coli27 registered studies
- DocetaxelExisting use: Adenocarcinoma, Breast cancer, Breast carcinoma and 19 more45.7% AI-predicted activityagainst E. coli50+ registered studies
- Fedratinib HydrochlorideExisting use: Myelofibrosis, Myeloproliferative disorder, Neoplasm and 1 more45.6% AI-predicted activityagainst E. coliNo documented evidence found
- IvabradineExisting use: Angina pectoris, Cardiovascular disease, Congestive heart failure and 1 more45.5% AI-predicted activityagainst E. coli50+ registered studies
- Pimavanserin TartrateExisting use: Hallucinations, Parkinson disease, Psychosis45.4% AI-predicted activityagainst E. coli46 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis45.2% AI-predicted activityagainst E. coli50+ registered studies
- RescinnamineExisting use: Hypertension45.2% AI-predicted activityagainst E. coliNo documented evidence found
- EluxadolineExisting use: Diarrheal disease, Irritable bowel syndrome45.1% AI-predicted activityagainst E. coli10 registered studies
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis45.0% AI-predicted activityagainst E. coli7 registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease44.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Open Label Safety Study in Acute Treatment of Migraine
NCT03266588 · start 2017-08-30
Registered record
- Registry ID
- NCT03266588
- Conditions
- Migraine, With or Without Aura
- Interventions
- Rimegepant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2017-08-30
- Completion
- 2019-07-15
- Enrolment
- 3,019
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine, With or Without AuraInterventionRimegepantPhasePhase 2 / Phase 3Registry statusCompletedSafety and Efficacy in Adult Subjects With Acute Migraines
NCT03237845 · start 2017-07-27
Registered record
- Registry ID
- NCT03237845
- Conditions
- Migraine, With or Without Aura
- Interventions
- Rimegepant; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-07-27
- Completion
- 2018-01-31
- Enrolment
- 1,499
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine, With or Without AuraInterventionRimegepant; PlaceboPhasePhase 3Registry statusCompletedStudy to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
NCT01445067 · start 2011-11
Registered record
- Registry ID
- NCT01445067
- Conditions
- Migraine
- Interventions
- BMS-927711 (CGRP Antagonist); BMS-927711 (CGRP Antagonist)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2012-09
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraineInterventionBMS-927711 (CGRP Antagonist); BMS-927711 (CGRP Antagonist)PhasePhase 1Registry statusCompletedDose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
NCT01430442 · start 2011-10
Registered record
- Registry ID
- NCT01430442
- Conditions
- Migraine; Acute Treatment of Migraine
- Interventions
- Rimegepant; Placebo; Sumatriptan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-10
- Completion
- 2012-05
- Enrolment
- 1,026
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine; Acute Treatment of MigraineInterventionRimegepant; Placebo; SumatriptanPhasePhase 2Registry statusCompletedAn Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
NCT03934086
Registered record
- Registry ID
- NCT03934086
- Conditions
- Migraine
- Interventions
- rimegepant
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraineInterventionrimegepantPhaseNot recordedRegistry statusNo longer available